{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:33:46Z","timestamp":1771043626035,"version":"3.50.1"},"reference-count":47,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T00:00:00Z","timestamp":1686268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nutrients"],"abstract":"<jats:p>The association between intravenous iron substitution therapy and hypophosphatemia was previously reported in patients with iron deficiency anemia. However, the extent of hypophosphatemia is thought to depend on the type of iron supplementation. We hypothesized that the intravenous application of ferric carboxymaltose and iron sucrose leads to a different longitudinal adaptation in serum phosphate levels. In this open-label pilot study, a total of 20 patients with inflammatory bowel diseases or iron deficiency anemia were randomly assigned to one of two study groups (group 1: ferric carboxymaltose, n = 10; group 2: iron sucrose, n = 10). Serum values were controlled before iron substitution therapy, as well as 2, 4, and 12 weeks after the last drug administration. The primary objective of the study was the longitudinal evaluation of serum phosphate levels after iron substitution therapy with ferric carboxymaltose and iron sucrose. The secondary objective was the longitudinal investigation of calcium, 25-hydroxyvitamin D (25(OH)D), intact parathyroid hormone, procollagen type 1 amino-terminal propeptide (P1NP), beta-CrossLaps (CTX), hemoglobin (Hb), iron, ferritin, and transferrin saturation levels. Two weeks after drug administration, phosphate levels were significantly lower (p &lt; 0.001) in group 1 and ferritin levels were significantly higher (p &lt; 0.001) in group 1. Phosphate levels (0.8\u20131.45 mmol\/L) were below the therapeutic threshold and ferritin levels (10\u2013200 ng\/mL for women and 30\u2013300 ng\/mL for men) were above the therapeutic threshold in group 1. P1NP (15\u201359 \u00b5g\/L) and CTX (&lt;0.57 ng\/mL) levels were above the therapeutic threshold in group 2. Four weeks after drug administration, significant differences were still observed between both study groups for phosphate (p = 0.043) and ferritin (p = 0.0009). All serum values except for Hb were within the therapeutic thresholds. Twelve weeks after drug administration, no differences were observed in all serum values between both study groups. Hb values were within the therapeutic threshold in both study groups. Serum 25(OH)D levels did not differ between both study groups throughout the whole study period and remained within the therapeutic threshold.<\/jats:p>","DOI":"10.3390\/nu15122693","type":"journal-article","created":{"date-parts":[[2023,6,9]],"date-time":"2023-06-09T08:37:33Z","timestamp":1686299853000},"page":"2693","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of Intravenous Iron Substitution on Serum Phosphate Levels and Bone Turnover Markers\u2014An Open-Label Pilot Study"],"prefix":"10.3390","volume":"15","author":[{"given":"Alexandra","family":"Struppe","sequence":"first","affiliation":[{"name":"St. Vincent Hospital Vienna, II Medical Department-Gastroenterology, Hepatology, Metabolic, and Inflammation Medicine, Academic Teaching Hospital of the Medical University of Vienna, 1060 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jakob E.","family":"Schanda","sequence":"additional","affiliation":[{"name":"AUVA Trauma Center Vienna-Meidling, Department for Trauma Surgery, 1120 Vienna, Austria"},{"name":"Ludwig Boltzmann Institute for Traumatology, 1200 Vienna, Austria"},{"name":"Austrian Cluster for Tissue Regeneration, 1200 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Baierl","sequence":"additional","affiliation":[{"name":"Insitute for Statistics and Operations Research, University of Vienna, 1090 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Watzl","sequence":"additional","affiliation":[{"name":"St. Vincent Hospital Vienna, II Medical Department-Gastroenterology, Hepatology, Metabolic, and Inflammation Medicine, Academic Teaching Hospital of the Medical University of Vienna, 1060 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4105-5361","authenticated-orcid":false,"given":"Christian","family":"Muschitz","sequence":"additional","affiliation":[{"name":"St. Vincent Hospital Vienna, II Medical Department-Gastroenterology, Hepatology, Metabolic, and Inflammation Medicine, Academic Teaching Hospital of the Medical University of Vienna, 1060 Vienna, Austria"},{"name":"HealthPi Medical Center, 1010 Vienna, Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/BF01496662","article-title":"Hypophosphatemia induced by intravenous administration of Saccharated iron oxide","volume":"61","author":"Okada","year":"1983","journal-title":"Klin. Wochenschr."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.bone.2009.06.017","article-title":"Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: Another form of FGF23-related hypophosphatemia","volume":"45","author":"Shimizu","year":"2009","journal-title":"Bone"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: An emerging complication","volume":"26","author":"Zoller","year":"2017","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/jbmr.3319","article-title":"Hypophosphatemia, Severe Bone Pain, Gait Disturbance, and Fatigue Fractures After Iron Substitution in Inflammatory Bowel Disease. A Case Report","volume":"33","author":"Bartko","year":"2018","journal-title":"J. Bone Min. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s00223-020-00664-9","article-title":"The Causes of Hypo- and Hyperphosphatemia in Humans","volume":"108","author":"Koumakis","year":"2021","journal-title":"Calcif. Tissue Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.amjmed.2005.02.014","article-title":"Hypophosphatemia: An update on its etiology and treatment","volume":"118","author":"Gaasbeek","year":"2005","journal-title":"Am. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.4103\/0971-5916.198664","article-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","volume":"144","author":"Goswami","year":"2016","journal-title":"Indian J. Med. Res."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM197710272971702","article-title":"Effect of hypophosphatemia on myocardial performance in man","volume":"297","author":"Wheeler","year":"1977","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0736-4679(02)00578-4","article-title":"Serum phosphate abnormalities in the emergency department","volume":"23","author":"Shiber","year":"2002","journal-title":"J. Emerg. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1001\/jama.1976.03270130042026","article-title":"Proximal myopathy caused by latrogenic phosphate depletion","volume":"236","author":"Ravid","year":"1976","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"245","DOI":"10.2147\/TCRM.S243462","article-title":"Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review","volume":"8","author":"Glaspy","year":"2020","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/01.mnh.0000447020.74593.6f","article-title":"Coupling fibroblast growth factor 23 production and cleavage: Iron deficiency, rickets, and kidney disease","volume":"23","author":"Wolf","year":"2014","journal-title":"Curr. Opin. Nephrol. Hypertens."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.lpm.2017.09.028","article-title":"Diagnosis of hyperferritinemia in routine clinical practice","volume":"46","author":"Lorcerie","year":"2017","journal-title":"La Presse M\u00e9dicale"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.revmed.2014.12.007","article-title":"Diagnosis of an increased serum level of ferritin","volume":"36","author":"Lorcerie","year":"2015","journal-title":"La Rev. Med. Interne"},{"key":"ref_15","first-page":"760","article-title":"Serum ferritin: Past, present and future","volume":"1800","author":"Wang","year":"2010","journal-title":"BBA"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/bmj.4.5834.206","article-title":"Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload","volume":"4","author":"Jacobs","year":"1972","journal-title":"Br. Med. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.blre.2008.08.001","article-title":"Ferritin for the clinician","volume":"23","author":"Knovich","year":"2009","journal-title":"Blood Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1056\/NEJMcpc049016","article-title":"Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Laboratory reference values","volume":"351","author":"Kratz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/BF02598003","article-title":"Laboratory diagnosis of iron-deficiency anemia: An overview","volume":"7","author":"Guyatt","year":"1992","journal-title":"J. Gen. Intern. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1365-2141.1993.tb03225.x","article-title":"Screening for iron deficiency: An analysis based on bone-marrow examinations and serum ferritin determinations in a population sample of women","volume":"85","author":"Hallberg","year":"1993","journal-title":"Br. J. Haematol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Darton, T.C., Blohmke, C.J., Giannoulatou, E., Waddington, C.S., Jones, C., Sturges, P., Webster, C., Drakesmith, H., Pollard, A.J., and Armitage, A.E. (2015). Rapidly Escalating Hepcidin and Associated Serum Iron Starvation Are Features of the Acute Response to Typhoid Infection in Humans. PLoS Negl. Trop. Dis., 22.","DOI":"10.1371\/journal.pntd.0004029"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/ajcn\/nqz201","article-title":"Changes in micronutrient and inflammation serum biomarker concentrations after a norovirus human challenge","volume":"110","author":"Williams","year":"2019","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_23","first-page":"28","article-title":"Comparing the effectiveness and cost-effectiveness of facility-versus community-based distribution of micronutrient powders in rural Uganda","volume":"1502","author":"Namaste","year":"2021","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1373\/clinchem.2016.259085","article-title":"Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease","volume":"63","author":"Greenblatt","year":"2017","journal-title":"Clin. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/s00223-009-9309-8","article-title":"Biology and clinical significance of tartrate-resistant acid phosphatases: New perspectives on an old enzyme","volume":"85","author":"Janckila","year":"2009","journal-title":"Calcif. Tissue Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"501","DOI":"10.2147\/CIA.S242288","article-title":"Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update","volume":"15","author":"Nagy","year":"2020","journal-title":"Clin. Interv. Aging."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3803\/EnM.2020.35.1.55","article-title":"Potential Biomarkers to Improve the Prediction of Osteoporotic Fractures","volume":"35","author":"Kim","year":"2020","journal-title":"Endocrinol. Metab."},{"key":"ref_28","first-page":"304","article-title":"The role of biochemical markers of bone turnover in the diagnosis of osteoporosis and predicting fracture risk","volume":"92","author":"Mohamed","year":"2014","journal-title":"Tunis Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF03256280","article-title":"Biomarkers for osteoporosis management: Utility in diagnosis, fracture risk prediction and therapy monitoring","volume":"12","author":"Garnero","year":"2008","journal-title":"Mol. Diagn Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100862","DOI":"10.1016\/j.mam.2020.100862","article-title":"Intravenous iron supplementation therapy","volume":"75","author":"Schaefer","year":"2020","journal-title":"Mol. Asp. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of Iron Isomaltoside vs. Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials","volume":"323","author":"Wolf","year":"2020","journal-title":"JAMA"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"116202","DOI":"10.1016\/j.bone.2021.116202","article-title":"Hypophosphatemia after intravenous iron therapy: Comprehensive review of clinical findings and recommendations for management","volume":"154","author":"Schaefer","year":"2022","journal-title":"Bone"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/gutjnl-2022-327897","article-title":"Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in patients with iron deficiency anaemia due to inflammatory bowel disease: A randomised clinical trial","volume":"72","author":"Zoller","year":"2023","journal-title":"Gut"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/ndt\/gfz196","article-title":"Phosphate and bone fracture risk in chronic kidney disease patients","volume":"36","author":"Fusaro","year":"2021","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/jbmr.3094","article-title":"Serum phosphate is as- sociated with fracture risk: The Rotterdam study and MrOS","volume":"32","author":"Koek","year":"2017","journal-title":"J. Bone Miner. Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/cen.13363","article-title":"Serum phosphorus levels and fracture following renal transplantation","volume":"87","author":"Aleksova","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1210\/clinem\/dgab852","article-title":"Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose","volume":"107","author":"Schaefer","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1210\/jc.2016-2930","article-title":"Effects of genetic and non genetic factors on total and bioavailable 25(OH)D responses to vitamin D supplementation","volume":"102","author":"Yao","year":"2017","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1210\/jc.2010-2704","article-title":"The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: What clinicians need to know","volume":"96","author":"Ross","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s00394-015-0859-4","article-title":"A dose-response study of vitamin D3 supplementation in healthy Chinese: A 5-arm randomized, placebo-controlled trial","volume":"55","author":"Yao","year":"2016","journal-title":"Eur. J. Nutr."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00198-017-3955-x","article-title":"The associations between serum 25-hydroxyvitamin D level and the risk of total fracture and hip fracture","volume":"28","author":"Feng","year":"2017","journal-title":"Osteoporos. Int."},{"key":"ref_44","first-page":"257","article-title":"Fracture prevention with vitamin D supplementation: A meta-analysis of randomized controlled trials","volume":"293","author":"Willett","year":"2005","journal-title":"JAMA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1056\/NEJMoa1109617","article-title":"A pooled analysis of vitamin D dose requirements for fracture prevention","volume":"367","author":"Willett","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.bone.2014.04.026","article-title":"The role of vitamin D in human fracture healing: A systematic review of the literature","volume":"64","author":"Gorter","year":"2014","journal-title":"Bone."},{"key":"ref_47","first-page":"53","article-title":"What is the role of vitamin D supplementation in acute fracture patients? A systematic review and meta-analysis of the prevalence of hypovitaminosis D and supplementation efficacy","volume":"30","author":"Sprague","year":"2016","journal-title":"J. Orthop. Traumatol."}],"container-title":["Nutrients"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/12\/2693\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:51:31Z","timestamp":1760125891000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6643\/15\/12\/2693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,9]]},"references-count":47,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["nu15122693"],"URL":"https:\/\/doi.org\/10.3390\/nu15122693","relation":{},"ISSN":["2072-6643"],"issn-type":[{"value":"2072-6643","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,9]]}}}